Resources
News

Verrill Welcomes Health Care Attorney Sarah V. Ferranti

December 12, 2019 Press Releases

(December 12, 2019) – Verrill is pleased to welcome attorney Sarah V. Ferranti to the firm’s nationally recognized Health Care & Life Sciences Group. Ferranti joins Verrill’s Boston office with more than 11 years of experience as a health care and life sciences attorney.

Ferranti focuses her practice on human subjects research, privacy, fraud and abuse compliance, and accountable care. She also has extensive experience advising on controlled substance matters, pharmacy matters, and the 340B program.

Prior to joining Verrill, Ferranti was a senior attorney in the health care group at Ropes & Gray LLP, where she counseled clients ranging from hospitals, universities, and research institutions to biotech, pharmaceutical, diagnostic, and device companies on multifaceted regulatory, compliance, and transactional matters.

Ferranti received her bachelor’s degree from Tufts University, summa cum laude, and earned her law degree from Vanderbilt University Law School.

Firm Highlights

Matter

Conflicts of Interest

Reviewed medical center's systems, policies and procedures for identifying, assessing, and managing investigator and institutional conflicts of interest.

Matter

European Union GDPR—Institution

Counseled a preeminent health system and academic medical center on its compliance with the European Union General Data Protection Regulation (GDPR) in relation to its clinical and research activities, including its international research studies...

Publication/Podcast

Responsible Research During the COVID-19 Pandemic

News

Michael K. Fee to Lead Verrill’s Health Care and Life Sciences Defense Practice

(January 22, 2020) – Verrill is pleased to welcome Michael K. Fee to the firm’s Boston office as a Partner in its nationally recognized Health Care & Life Sciences Group and as the leader...

Publication/Podcast

COVID-19 Expanded Access Template

We are aware that many companies and health care providers are working to expedite the transfer of investigational drugs that may be helpful in treating patients suffering from COVID-19. Although these expanded access arrangements...

Matter

Common Rule

Guided multiple clients through the implementation of the revised HHS regulations (the "Common Rule"), including reviewing and revising policies and procedures, and assisting with institutional approaches to implementation.

Publication/Podcast

COVID-19: FDA Clinical Trial Guidance

On March 18, 2020, the U.S. Food & Drug Administration (“FDA”) published guidance for clinical trial sponsors, investigators, and institutional review boards (“IRBs”) on conducting clinical trials in the midst of the COVID-19 pandemic...

Matter

Multi-Site Global Research

Developed and negotiated site and coordinating center agreements in connection with a multi-site, international, National Institutes of Health (NIH)-funded study, and advised on regulatory issues related to the conduct of the study and subsequent...

Publication/Podcast

Due to COVID-19, Federal Agencies Relax Requirements Regarding the Provision of Telehealth Services

In the past few days, in an effort to help keep Medicare beneficiaries healthy during the COVID-19 pandemic, key federal agencies within the U.S. Department of Health and Human Services (“HHS”) and the U.S...

Publication/Podcast

Updated FDA COVID-19 Guidance for Conduct of Clinical Trials

On March 27, 2020, the U.S. Food & Drug Administration (“FDA”) updated its prior guidance on the “ Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic ,” with an appendix adding a...